A Phase I Study of Safety, Pharmacokinetic and Efficacy of Orally Administered APG-5918 in Patients With Advanced Solid Tumors or Hematologic Malignancies
Considering participating in a START clinical trial?
Study Summary
To evaluate the safety and efficacy data of APG-5918 in subjects with histologically- and/or cytologically-confirmed advanced solid tumors or non-Hodgkin's lymphoma (NHL) that have progressed or intolerant after treatment with approved therapies or for which there are no standard therapies available.
To evaluate the safety, pharmacokinetics, and preliminary efficacy of APG-5918 in patients with solid tumors or hematologic malignancies.
To evaluate the safety, tolerability, and to determine the dose-limiting toxicity, maximum tolerated dose, and recommended Phase II dose (RP2D) of orally administered APG-5918.
- 1The Eastern Cooperative Oncology Group (ECOG) performance status is 0-1 (dose escalation) and 0-2 (dose extension).2Life expectancy > 3 months.3Having a malignant tumor: locally advanced or metastatic solid tumor or recurrent or refractory non-Hodgkin lymphoma, plasma cell tumor confirmed by histology or cytology, and whose disease has progressed after receiving existing treatments known to produce clinical benefit.4For B-cell lymphoma candidates: EZH2 mutation status has been confirmed or the candidate is willing to undergo EZH2 mutation status testing. Mutation status will not affect the candidate's eligibility.5For sarcoma subjects: subjects with epithelioid sarcoma or sarcoma who have confirmed evidence of abnormal SMARCB1 status are preferred.6For prostate cancer patients: the patient must have evidence of castration resistance.7It has good hematology, liver function and kidney function.8The QTcF interval was ≤470ms for all sexes.9For subjects with solid tumors, brain metastases must be stable and neurological symptoms must be clinically controlled (subjects without brain metastases may also be included); for subjects with hematologic malignancies, subjects should have no known central nervous system (CNS) lesions.10Fertility-bearing male and female subjects and their partners are willing to practice true abstinence or use a method of contraception deemed effective by the investigators throughout the treatment period and for at least 3 months after the last dose of the study drug.11The patient must be able to understand and be willing to sign a written informed consent form (the informed consent form must be signed by the patient before any study-specific procedure).12Willing and able to comply with research procedures and follow-up examinations.
- Inclusion Criteria:
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 in dose escalation or 0 to 2 in dose expansionHas a life expectancy of >3 monthsHas a malignancy: with histologically or cytologically confirmed locally advanced or metastatic solid tumors or relapsed or refractory Non-Hodgkin's Lymphoma (NHL) who have disease progression after treatment with available therapies that are known to confer clinical benefit.has measurable disease based on RECIST 1.1 for advanced solid tumors including but not limited to nasopharyngeal carcinoma, castration-resistant prostate cancer, gastric cancer, ovarian clear cell carcinoma, mesothelioma, and sarcomahas measurable disease based on Non-Hodgkin's Lymphoma Cheson response criteria for NHLFor subjects with B cell lymphoma: has documented EZH2 mutation status or be willing to perform EZH2 mutation status testingFor subjects with sarcoma: patients with epithelioid sarcoma or sarcoma with confirmed evidence of aberrant SMARCB1 status is preferredFor subjects with prostate cancer: patients must have evidence of castration resistance (as evidenced by confirmed elevated prostate-specific antigen (PSA) (per Prostate Cancer Working Group [PCWG3] criteria) and serum testosterone of castrate levels (i.e. ≤ 50 ng/dL))Adequate hematologic function defined as:ANC ≥1.0 x 10˄9/L independent of growth factor support within 7 days of the first dose with study drugHemoglobin ≥9 g/dL without transfusion or growth factor support within 7 days of the first dose of study drugPlatelet count ≥ 75 x 10˄9/L without transfusion support within 7 days of the first dose of study drugAdequate hepatic and renal function defined as:AST and ALT ≤ 3 x upper limit of normal (ULN) (≤ 5 x ULN if liver metastases)Calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault formulaTotal Bilirubin ≤1.5 x ULN (Except if considered secondary to Gilbert's syndrome and primarily indirect bilirubinemia)PT and aPTT ≤2 x ULNTroponin ≤ 2 x ULNQTcF interval ≤470ms for all genders (mean (triplicate) n =3), measured between 2-5 minutes apartStable brain metastases with clinically controlled neurologic symptomsWillingness to use contraception by either true abstinence or the use of a method that is deemed effective by the investigator by both males and female patients of childbearing potential and their partners throughout the treatment period and for at least three months following the last dose of study drug. Note: Female participants of non-child-bearing potential are defined as:surgically sterile,postmenopausal for 12 months, orreceiving a stable dose of oral, implanted, transdermal or injectable contraceptive for at least 3 months with the last dose of injectable contraceptive within 2 months (Nonsurgical menopause history must be confirmed by follicle-stimulating hormone and luteinizing hormone levels as defined by established laboratory ranges)Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the patient prior to any study-specific procedures)Willingness and ability to comply with study procedures and follow-up examination
- 1Currently receiving concomitant anticancer therapy; or having received any experimental treatment within 14 days prior to the first dose of the investigational drug or within 5 times its molecular half-life; or having undergone T-cell redirection therapy within 28 days; or having previously received radiation therapy to more than 25% of the bone marrow.2The patients had received antitumor steroid treatment within 7 days prior to the first administration of the study drug.3The toxicity caused by previous radiotherapy, targeted therapy, immunotherapy or chemotherapy drugs persists and has not recovered to grade <2, excluding hair loss or vitiligo.4Patients with gastrointestinal diseases that researchers believe may affect the absorption of APG-5918.5Therapeutic doses of anticoagulants and antiplatelet drugs are prohibited; low doses of anticoagulants are permitted to maintain the patency of the central venous catheter.6The patient had received a biologic within 7 days prior to the first administration of the investigational drug.7Researchers determined that previous surgical procedures had not fully healed. Participants who had undergone major surgery within 28 days prior to enrollment, and those who had undergone minor surgery within 14 days prior to enrollment, were included in the study.8For subjects with multiple myeloma, the corrected calcium levels were sufficient.9For patients with multiple myeloma, plasma exchange or hemodialysis is required within 14 days prior to enrollment.10Severe heart disease.11Based on clinical evaluation, symptomatic brain metastases are considered due to tumor involvement of the central nervous system (CNS). Subjects with asymptomatic CNS tumors who have received treatment and have discontinued steroids (for CNS tumors) for >28 days are eligible for enrollment.12Active, symptomatic fungal, bacterial, and/or viral infections, including HIV, hepatitis B, hepatitis C, COVID-19, etc.13The patient had previously received treatment with an ectodermal developmental protein (EED) inhibitor.14Simultaneously use drugs that prolong the QT interval.15The patient has a history of torsades de pointes.16Concomitant POEMS syndrome, plasma cell leukemia, or known amyloidosis.17Subjects who are known or suspected to be allergic or hypersensitive to APG-5918 or other drugs/compounds similar to EED inhibitors, or who are allergic to enzalutamide or to esartuximab or pomalidomide.18Non-Hodgkin's lymphoma patients who have previously received allogeneic stem cell transplantation.19Severe and/or uncontrollable medical conditions that researchers believe may affect an individual's safety or impair the assessment of research results.20Long-term steroid treatment.twenty onePregnant or breastfeeding female subjects.
- Exclusion Criteria:
- Receiving concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, with the exception of hormones for hypothyroidism or estrogen replacement therapy (ERT), anti-estrogen analogs, agonists required to suppress serum testosterone levels); or any investigational therapy within 14 days or 5 times of half-life of the molecule prior to the first dose of study drugSteroid therapy for anti-neoplastic intent within 7 days prior to the first dose of the study drugContinuance of toxicities due to prior radiotherapy, targeted therapy, immunotherapy or chemotherapeutic agents that do not recover to < Grade 2, except alopecia or leukodermiaHas gastrointestinal conditions that could affect the absorption of APG-5918 in the opinion of the InvestigatorUse of therapeutic doses of anti-coagulants is excluded, along with antiplatelet agents; low-dose anticoagulation medications that are used to maintain the patency of a central intravenous catheter are permittedReceived a biologic (G-CSF, GM-CSF, or erythropoietin) within 7 days prior to the first dose of the study drugFailure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry.Severe cardiac conditions defined as:New York Heart Association (NYHA) class III or IV cardiac disease, including preexisting uncontrolled clinically significant arrhythmia, congestive heart failure, or cardiomyopathyUnstable angina, myocardial infarction, or a coronary revascularization procedure within ≤ 3 months prior to initiation of study treatmentEchocardiography showing left ventricular ejection fraction (LVEF) < 50%poorly controlled hypertension, or history of poor compliance with antihypertensive drug regimensSymptomatic brain metastases per clinical evaluation due to tumor involvement of the central nervous system (CNS). Patients with CNS tumors that have been treated are asymptomatic and who have discontinued steroids (for the treatment of CNS tumors) for ≤ 28 days may be enrolled.Active symptomatic fungal, bacterial, and/or viral infection. Patients with well controlled human immunodeficiency virus (HIV), hepatitis B or C can be enrolled.Prior treatment with embryonic ectoderm development (EED) inhibitorsConcurrent treatment with QT interval-prolonging drugsMedical history of Torsades de PointesPatients with known or suspected allergy or hypersensitivity to drugs/compounds similar in composition to APG-5918 or other EED inhibitorsAny other condition or circumstance of that would, in the opinion of the investigator, make the patient unsuitable for participation in the studyOther malignant diseases than the ones being treated in this study with the exception of: cured malignancy without recurrence within 3 years prior to study entry; completely resected basal cell and squamous cell skin cancer; completely resected carcinoma in situ of any typeNon-Hodgkin lymphoma patients who have received prior allogeneic stem cell transplantSevere and/or uncontrolled medical conditions that in the investigator's opinion could affect the safety of individual or impair the assessment of study resultLong-term steroid therapy, except for the following: 10 mg prednisone (or equivalent) daily or lower doses of steroids for control of nausea, vomiting, active autoimmune disease and seasonal allergies or prevention of adrenocortical insufficiency Note: topical steroids or inhaled steroids are allowedPregnant (confirmed by human chorionic gonadotropin (HCG) testing) or lactating women
Clinical Study Information for Healthcare Providers
By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.